INFORMAZIONI SU QUESTO EPISODIO
What factors come into play when deciding whether to use liver-directed therapy or systemic therapies for neuroendocrine tumors? In this episode of the BackTable Tumor Board Podcast, Dr. Lingling Du, Dr. Chih-Yi Liao, and Dr. Abdul Khan discuss the structure of a multidisciplinary tumor board and how they approach decision-making for patients with neuroendocrine tumors. The conversation explores who benefits most from liver-directed therapy, optimal timing for intervention, and the importance of individualized treatment planning.
---
Get the BackTable app
https://www.backtable.com/app
---
Timestamps
00:00 - Introduction
02:04 - How The NET Tumor Board Works at UChicago
04:15 - Patients Who Benefits From Liver-Directed Therapy
10:45 - Non-candidates for Liver-Directed Therapy
13:37 - Choosing Modalities of Therapy: Bland TACE, Y90 and Ablation
15:16 - RETNET Trial Takeaways
21:38 - Histotripsy for Neuroendocrine Tumors
25:42 - Sequencing Liver-Directed Therapy With Systemic Therapy or PRRT
28:11 - Case One: Heavy Liver Burden
33:12 - Case Two: Aggressive NEC & Miracle Response
38:23 - Wrap Up and Credits
---
More about this episode
The doctors review contraindications, modality selection, and sequencing with systemic therapy and PRRT before breaking down the RETNET trial, which shows similar hepatic progression-free survival between bland embolization and conventional TACE. They then discuss two patient cases, highlighting upfront embolization for heavy low-grade liver burden and repeat Y90 for oligometastatic high-grade neuroendocrine carcinoma with durable control.
---
Resources
RETNET Trial
https://www.jvir.org/article/S1051-0443(25)00027-2/fulltext
---
BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care.
Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.
► https://www.backtable.com/app
